Artiva Biotherapeutics (ARTV) EBITDA Margin (2023 - 2024)
Artiva Biotherapeutics (ARTV) posted quarterly EBITDA Margin of 5773.71% for Q1 2024, down 1033.52% quarter-over-quarter from 509.36% in Q4 2023.
Powered by 
Analysis
Artiva Biotherapeutics (ARTV) EBITDA Margin (2023 - 2024) Analysis & Trends
Artiva Biotherapeutics (ARTV) has reported EBITDA Margin for 2 consecutive years, with 5773.71% the latest figure, recorded in Q1 2024.
- In Q1 2024, EBITDA Margin changed N/A year-over-year to 5773.71%; the TTM figure through Dec 2024 stood at 26806.37% (changed N/A YoY), while the FY2024 annual figure was 26805.58%, down 2671400.0% from the prior year.
- EBITDA Margin slipped to 5773.71% in Q1 2024 per ARTV's latest filing, from 509.36% in the prior quarter.
- Across five years, EBITDA Margin topped out at 40.56% in Q3 2023 and bottomed at 5773.71% in Q1 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Artiva Biotherapeutics | 441.23 Mn | 441.23 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2024 | -5,773.71% |
| Dec 31, 2023 | -509.36% |
| Sep 30, 2023 | 40.56% |
| Jun 30, 2023 | -338.12% |